Revolutionizing Oral Drug Development in Atopic Dermatitis
Time: 11:30 am
day: Day 2 AM - Track A
Details:
- Championing the specificity of the CCR4 target in atopic dermatitis
- Delivering an orally administered small molecule with efficacious potency
- Validating phase 1 studies with transcriptomic biomarker analyses to enable phase 2 progression
